{"schema_version":"secwatch.filing_event.v1","accession":"0001753926-25-001500","form_type":"8-K/A","ticker":"PTHS","cik":"0001919246","company_name":"Pelthos Therapeutics Inc.","filed_at":"2025-09-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:45.588664+00:00","generated_at":"2026-05-17T06:33:25.653243+00:00","sec_items":["9.01","2.01","2.02"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Pelthos (PTHS) files LNHC unaudited financials and pro forma data post-merger closed July 1, 2025","bullets":["Merger closed July 1, 2025; issued ~31,278 Series A Preferred shares to Ligand; PIPE raised ~$50.1M gross.","LNHC unaudited balance sheets as of June 30, 2025 and 2024; pro forma financial info provided for combined entity.","ZELSUVMI (berdazimer gel) FDA approved Jan 2024 for molluscum contagiosum; 13% royalty to Ligand on worldwide sales.","Nomis RoyaltyVest receives 1.5% royalty on ZELSUVMI net sales; additional royalty agreements with Ligand and Madison.","Company holds exclusive license from Ligand for ZELSUVMI ex-Japan; 19,265 sq ft facility in Durham, NC."],"urls":{"canonical":"https://secwatch.observer/filing/0001753926-25-001500","json":"https://secwatch.observer/filing/0001753926-25-001500.json","markdown":"https://secwatch.observer/filing/0001753926-25-001500.md","text":"https://secwatch.observer/filing/0001753926-25-001500.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1919246/000175392625001500/0001753926-25-001500-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1919246/000175392625001500/g084946_8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:33:25.653243+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"44f51db19d684d28f12bee82085fca46c2332cf9","claim":"Pelthos Therapeutics Inc. completed an acquisition involving LNHC, Inc. and Ligand Pharmaceuticals Incorporated (closed 2025-07-01).","evidence_excerpt":"On July 1, 2025, Channel Therapeutics Corporation, Merger Sub, LNHC, and solely for the purposes of Article III thereof, Ligand consummated the Merger","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1919246/000175392625001500/0001753926-25-001500-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"LNHC, Inc. and Ligand Pharmaceuticals Incorporated"},{"label":"Closing","value":"2025-07-01"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}